Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Volker Daniel

Showing results (101-110 of 107) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 107 results.
Transplantation|November 14, 2008
Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedicationBritta Höcker, John M Kovarik, Volker Daniel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2021
Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal AdenocarcinomaJacek Hajda, Barbara Leuchs, Assia L Angelova, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 3, 2017
Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma TrialKarsten Geletneky, Jacek Hajda, Assia L Angelova, et al.
The Journal of Clinical Investigation|January 29, 2020
Phase I trial of donor-derived modified immune cell infusion in kidney transplantationChristian Morath, Anita Schmitt, Christian Kleist, et al.
Journal of the American Society of Nephrology : JASN|September 22, 2022
Induction of Long-Lasting Regulatory B Lymphocytes by Modified Immune Cells in Kidney Transplant RecipientsChristian Morath, Matthias Schaier, Eman Ibrahim, et al.
BMJ Open|November 11, 2022
Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trialChristian Morath, Anita Schmitt, Michael Schmitt, et al.
Frontiers in Immunology|July 24, 2023
Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantationMatthias Schaier, Christian Morath, Lei Wang, et al.
Pageof 11

Showing results (101-110 of 107) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 107 results.
Transplantation|November 14, 2008
Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedicationBritta Höcker, John M Kovarik, Volker Daniel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2021
Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal AdenocarcinomaJacek Hajda, Barbara Leuchs, Assia L Angelova, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 3, 2017
Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma TrialKarsten Geletneky, Jacek Hajda, Assia L Angelova, et al.
The Journal of Clinical Investigation|January 29, 2020
Phase I trial of donor-derived modified immune cell infusion in kidney transplantationChristian Morath, Anita Schmitt, Christian Kleist, et al.
Journal of the American Society of Nephrology : JASN|September 22, 2022
Induction of Long-Lasting Regulatory B Lymphocytes by Modified Immune Cells in Kidney Transplant RecipientsChristian Morath, Matthias Schaier, Eman Ibrahim, et al.
BMJ Open|November 11, 2022
Individualised immunosuppression with intravenously administered donor-derived modified immune cells compared with standard of care in living donor kidney transplantation (TOL-2 Study): protocol for a multicentre, open-label, phase II, randomised controlled trialChristian Morath, Anita Schmitt, Michael Schmitt, et al.
Frontiers in Immunology|July 24, 2023
Five-year follow-up of a phase I trial of donor-derived modified immune cell infusion in kidney transplantationMatthias Schaier, Christian Morath, Lei Wang, et al.
Pageof 11